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[1] S. Pszona et al., Nucl. Instrum. and Meth. A 447, 601 (2000) [2] V. Conte et al., New J. Phys. 14, 093010, (2012) [3] G. Garty et al., Radiat. Prot. Dosim. 99, 325 (2002) [4] B. Grosswendt, Radiat. Prot. Dosim. 110, 789 (2004) [5] H Palmans, H Rabus, et al., Br. J. Radiol. 87: 20140392 (2015) [6] http://www.ptb.de/emrp/bioquart.html [7] http://www.lnl.infn.it/~microdos/MITRA.html [8] D. Moro et al., INFN-LNL-Report 239, 178-179 (2013) [9] G. Hilgers et al., INFN-LNL-Report 240, 129-130 (2014) [10] G. Hilgers et al., HIL Annual Report 2013 , 46-48 (2014 Brachytherapy in gynaecological cancers, and especially in cervix cancer, has greatly evolved during the last twenty years. For decades, brachytherapy has relied on x-ray orthogonal acquisitions, and prescription has been a matter of systems and schools, making reporting and comparisons difficult. Based on the developments of afterloaders and treatment planning systems, image-guided adaptive brachytherapy has emerged. This high precision technique combines all modern radiation requirements: image guidance, adaptation to tumor response, and short time treatment. Ten years ago, the GEC-ESTRO, in a will of harmonizing practices, published recommendations in cervical cancers regarding the definition of target-volumes and the reporting. These recommendations were rapidly adopted worldwide. During the last decade, multiple monocentric series, historical cohorts' comparisons, and a prospective multicentric study (STIC trial) demonstrated high local control rates with a limited morbidity in regard to classical data. These data are about to be confirmed by two large studies led by the Gyn GEC-ESTRO: Retro-EMBRACE and EMBRACE, which will establish MRI-guided brachytherapy as a gold standard. In addition, clear dose-volume effect relationships have been demonstrated between the modern dosimetric parameters and the probability of achieving local control or facing morbidity. The better knowledge of these correlations allowed the launch of EMBRACE II, a prospective study combing the best radiation modalities (EBRT and IGABT), with optimal and ambitious planning aims. In the near future, the large amount of data collected in the EMBRACE study (> 1 500 patients accrued) will allow the development of monograms integrating not only dosimetric parameters, but also criteria on comorbidities, clinical features, and tumor response to external beam radiotherapy. This would be of great help in adapting and personalizing treatment plans. Longer-term prospects include the development of alternative image modalities for guidance, such as endorectal ultrasound, cheaper and more accessible than MRI, or conversely, a more advanced and sophisticated image modality. Image-guided brachytherapy is also progressively declined in other gynecologic tumors, such as vagina cancer or nonoperable endometrial cancer. Introduction: Variation in shape, position and treatment response of both tumour and organs at risk are major challenges for accurate dose delivery in radiotherapy. Adaptive radiotherapy (ART) has been proposed to customise the treatment to these motion/response patterns of the individual patients, but increases workload thus challenge clinical implementation. This presentation presents a review of the clinically implemented ART in addition to in silico workflows that have been published on pelvic tumours.
Material and methods:
Initial identification of papers was based on searches in PubMed. For each tumour site (prostate, gynaecological [gynae] , bladder, ano-rectal), the identified papers were screened independently by two researches for selection of studies describing all processes of an ART workflow: treatment monitoring and evaluation, decision and execution of adaptations. Both brachytherapy (BT) and external beam studies were eligible in the review.
Result:
The review consisted of 43 clinical studies and 51 in silico studies. For prostate, 1219 patients were treated with offline re-planning workflows, mainly to adapt prostate motion relative to bony anatomy. For gynae 1155 patients were treated with online BT re-planning while 25 ano-rectal cancer patients were treated with offline re-planning, all to account for tumour regression detected by MRI/CT. For bladder and gynae, 161 and 64 patients respectively, were treated with library-based online plan selection to account for target volume and shape variations (Figure) . In comparison to non-ART, sparing of rectum (prostate and bladder cancer), bladder (ano-rectal cancer) and bowel cavity (gynae and bladder cancer) was reported with ART.
Conclusion:
Implementations of ART were dominated by offline re-planning and online BT re-planning, although recently online plan selection workflows have increased with the availability of cone-beam-CT. Advantageous dosimetric and outcome related patterns using ART was documented by the studies included the review. Despite this, clinical implementations have been scarce, especially regarding prostate and the vast amount of in silico studies available. Identified challenges, hindering successful clinical implementations, were re-contouring of target/OARs in addition to patient selection, aiding the focus of the adaptations to the more challenging patients.
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The challenges of ART from a physician's perspective S. Nuyts 1 University Hospital Gasthuisberg, Leuven, Belgium 1 Currently, with our highly conformal modulated radiotherapy techniques, we are capable of delivering high radiation doses to tumour volumes, whilst minimizing dose to the surrounding structures. However, today's radiotherapy is based on the dogmatic concept of unchanging anatomy of tumors, surrounding normal organs and tissues, where radiotherapy plans solely based on pre-treatment imaging are delivered invariably for several weeks of treatment. Conversely, during a course of curative radiotherapy, tumors and to some extend OARs change. In the field of head and neck cancer, tumor and lymph nodes shrink up to 3% per day, changing size, shape and position. External contour modifications result from loss of weight and muscle mass, altering the geometry of the disease in relation to OARs. This leads to changes in the anatomy of patients, impacting the dose distribution that may differ significantly from what was planned. In this context, considerable efforts have been put on adaptive radiotherapy (ART), i.e. to adapt the treatment delivery on the basis of changes in the tumor and/or normal tissues during the course of radiotherapy. The aim is then to compensate for under-dosage of the target volumes or overdosage of OARs. Re-imaging and re-planning evidently result in an extra workload and cost. Therefore, although ART is an appealing concept, it is at present not used on a routine basis for all patients. The optimal implementation strategy regarding selection of patients and timing of imaging/replanning remains to be defined. Several groups are currently investigating these questions, and an overview of the results, from a physician's perspective will be presented.
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